Table II.
Maintenance of translocon component interactions during the translocation cycle
| Donor | Acceptor | Untreated | Puromycin | Pactamycin |
|---|---|---|---|---|
| SRα | Sec61α | 34.1 ± 5.2 | 31.6 ± 7.3 | 32.2 ± 4.2 |
| SRα | Sec61β | 16.0 ± 2.2 | 17.2 ± 3.3 | 18.8 ± 2.8a |
| TRAPα | Sec61α | 18.4 ± 6.4 | 13.6 ± 5.6a | 15.2 ± 4.9 |
| TRAPα | Sec61β | 13.6 ± 3.5 | 11.1 ± 3.1a | 11.8 ± 2.7 |
| TRAM | Sec61α | 17.6 ± 4.2 | 19.8 ± 2.9a | 19.7 ± 4.4 |
| TRAM | Sec61β | 12.8 ± 2.7 | 11.9 ± 2.0 | 10.4 ± 1.1a |
FRET efficiencies for the indicated donor–acceptor antibody pairs were measured and tabulated as in Table I.
a
Treatment is significant (P ≤ 0.01) compared with untreated cells using t test.